Tumor-associated carbohydrate antigens (TACAs) represent potential biomarkers for early detection of cancer as well as immunotherapeutic targets. For example, the extracellular glycoprotein MUC1 is overexpressed and aberrantly glycosylated in many types of cancers. The extracellular domain of the MUC-1 contains a variable number of tandem repeats (VNTR) of 20 amino acids residues with serine (Ser) or threonine (Thr) sites for O-glycosylation. Generally, aberrantly expressed O-Glycans aid in the metastasis of diseased cells, yet also distinguish diseased from healthy cells at the cell surface. This makes them good targets for cancer immunotherapy drugs and as biomarkers for cancer.
Z Biotech’s O-Glycan array can serve as a research tool for determining O-glycan immunodominant epitopes in cancers or to sensitively detect the glycan binding epitopes of autoantibodies that target unique O-glycan antigens.
O-Glycan Array Features
O-Glycans and Cancers
Typical Binding Assay Result from the O-Glycan Array
The O-glycan Array was assayed with biotinylated Helix pomatia agglutinin (HPA) lectin (10 μg/mL), followed by Streptavidin-Cy3. The array was scanned with a microarray scanner at 532nm wavelength. Positive control 1 and the marker show binding as expected, as well as terminal-GalNAc-containing O-glycans.